BioMarin Pharmaceutical Inc.
BMRN
$67.48
-$0.84-1.23%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 17.97% | 19.14% | 15.83% | 13.74% | 15.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.97% | 19.14% | 15.83% | 13.74% | 15.42% |
| Cost of Revenue | 9.96% | -6.96% | -23.46% | -22.25% | -22.24% |
| Gross Profit | 22.56% | 40.63% | 60.56% | 55.15% | 59.74% |
| SG&A Expenses | 2.33% | 17.10% | 12.55% | 7.07% | 7.39% |
| Depreciation & Amortization | -30.47% | -22.02% | -5.35% | -3.20% | -0.94% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.26% | 12.07% | 10.56% | 9.49% | 10.18% |
| Operating Income | 206.85% | 115.80% | 104.47% | 101.75% | 169.43% |
| Income Before Tax | 187.31% | 158.08% | 176.29% | 228.99% | 26.07% |
| Income Tax Expenses | 449.31% | 1,385.08% | 418.73% | 5,907.16% | 160.99% |
| Earnings from Continuing Operations | 154.62% | 119.21% | 156.61% | 186.89% | 18.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 154.62% | 119.21% | 156.61% | 186.89% | 18.43% |
| EBIT | 206.85% | 115.80% | 104.47% | 101.75% | 169.43% |
| EBITDA | 129.69% | 69.35% | 60.12% | 52.74% | 69.76% |
| EPS Basic | 151.39% | 116.68% | 154.11% | 183.46% | 16.20% |
| Normalized Basic EPS | 207.56% | 100.43% | 96.60% | 103.89% | 187.48% |
| EPS Diluted | 157.15% | 117.91% | 156.99% | 188.83% | 17.13% |
| Normalized Diluted EPS | 205.17% | 97.92% | 94.99% | 102.03% | 186.71% |
| Average Basic Shares Outstanding | 1.17% | 1.21% | 1.26% | 1.34% | 1.41% |
| Average Diluted Shares Outstanding | 2.73% | 2.89% | 2.86% | 3.16% | 2.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
